Identification of Selective and Potent Inhibitors of Fibroblast Activation Protein and Prolyl Oligopeptidase

Sarah E. Poplawski(Arisaph Pharmaceuticals (United States)), Jack H. Lai(Arisaph Pharmaceuticals (United States)), Youhua Li(Tufts University), Zhiping Jin(Tufts University), Yuxin Liu(Tufts University), Wengen Wu(Tufts University), Yong Hua Wu(Tufts University), Yuhong Zhou(Tufts University), James L. Sudmeier(Tufts University), David G. Sanford(Arisaph Pharmaceuticals (United States)), William W. Bachovchin(Arisaph Pharmaceuticals (United States))
Journal of Medicinal Chemistry
April 17, 2013
Cited by 123Open Access
Full Text

Abstract

Fibroblast activation protein (FAP) is a serine protease selectively expressed on reactive stromal fibroblasts of epithelial carcinomas. It is widely believed to play a role in tumor invasion and metastasis and therefore to represent a potential new drug target for cancer. Investigation into its biological function, however, has been hampered by the current unavailability of selective inhibitors. The challenge has been in identifying inhibitors that are selective for FAP over both the dipeptidyl peptidases (DPPs), with which it shares exopeptidase specificity, and prolyl oligopeptidase (PREP), with which it shares endopeptidase specificity. Here, we report the first potent FAP inhibitor with selectivity over both the DPPs and PREP, N-(pyridine-4-carbonyl)-d-Ala-boroPro (ARI-3099, 6). We also report a similarly potent and selective PREP inhibitor, N-(pyridine-3-carbonyl)-Val-boroPro (ARI-3531, 22). Both are boronic acid based inhibitors, demonstrating that high selectivity can be achieved using this electrophile. The inhibitors are stable, easy to synthesize, and should prove to be useful in helping to elucidate the biological functions of these two unique and interesting enzymes, as well as their potential as drug targets.


Related Papers

No related papers found

Powered by citation graph analysis